Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy

被引:77
|
作者
Cheng, SH
Jian, JJM
Tsai, SYC
Chan, KY
Yen, LK
Chu, NM
Tan, TD
Tsou, MH
Huang, AT
机构
[1] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan
[2] Koo Fdn Sun Yat Sen Canc Ctr, Clin Protocol Off, Taipei, Taiwan
[3] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiol, Taipei, Taiwan
[4] Koo Fdn Sun Yat Sen Canc Ctr, Dept Head & Neck Surg, Taipei, Taiwan
[5] Koo Fdn Sun Yat Sen Canc Ctr, Dept Lab & Pathol, Taipei, Taiwan
[6] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[7] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan
关键词
nasopharyngeal carcinoma; radiotherapy; chemotherapy; prognosis;
D O I
10.1016/S0360-3016(98)00092-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Concurrent chemotherapy and radiotherapy (CCRT) are effective in treatment of locoregionally advanced nasopharyngeal carcinoma (NPC). However, the prognostic factors after CCRT have not been evaluated. We therefore attempt to evaluate factors that influence treatment outcomes following CCRT. Methods and Materials: Seventy-four (5 in stage m and 69 in stage IV) patients with locoregionally advanced NPC were treated with CCRT. Radiotherapy was delivered either at 2 Gray (Gy) per fraction per day up to 70 Gy or 1.2 Gy, 2 fractions per day, up to 74.4 Gy. Concurrent chemotherapy consisted of cisplatin and 5-fluorouracil. Cos proportional-hazards model was used to analyze the prognostic factors which included age, gender, pathologic type, T? N, lactate dehydrogenase (LDH), and infiltration of the clivus. Results: The primary tumor control rate at 3 years was 96.7% (95% confidence interval [CI]: 92.5-100), distant metastasis-free survival 81.1%; (95% CI: 70.6-91.6), disease-free survival 77.0% (95% CI: 65.3-88.7), and overall survival 79.8% (95% CI: 69.2-90.4) with a median follow-up interval of 29 months (range 15-74 months). Cox proportional-hazards model revealed that infiltration of the clivus and serum level of LDH before treatment were the most two important factors that predict distant metastases. Infiltration of the clivus and the serum LDH Level greater than 410 Un were strongly associated with distant metastasis-free survival (p = 0.0004 and p = 0.0002, respectively). When these two risk factors were considered together, no distant metastasis was observed in 40 patients with both intact clivus and LDH less than or equal to 410 U/L. On the contrary, 13 of the remaining 34 patients with at least one risk factor developed distant metastasis (p = 0.0001). Conclusion: Our study demonstrates that CCRT can improve the primary tumor control of 96.7% and disease-free survival of 77.0% at 3-year follow-up. Distant metastasis, however, is the major cause of failure. Infiltration of the clivus by the tumor and LDH greater than 410 U/L are the two independent and useful prognostic factors in patients with locoregionally advanced NPC who were treated with CCRT. Good- and poor-risk patients can be distinguished by virtue of their having both conditions. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:755 / 762
页数:8
相关论文
共 50 条
  • [21] Induction Chemotherapy with Nedaplatin with 5-FU Followed by Intensity-modulated Radiotherapy Concurrent with Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
    Zheng, Jijun
    Wang, Ge
    Yang, Gary Y.
    Wang, Daoyuan
    Luo, Xizhong
    Chen, Chuan
    Zhang, Zhimin
    Li, Qiong
    Xu, Wen
    Li, Zengpeng
    Wang, Dong
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (05) : 425 - 431
  • [22] Concurrent chemotherapy and radiotherapy for nasopharyngeal carcinoma
    Mizowaki, T
    Okajima, K
    Nagata, Y
    Mitsumori, M
    Nishimura, Y
    Hiraoka, M
    RADIOLOGY, 2000, 217 : 140 - 140
  • [23] Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
    Wang Fangzheng
    Sun Quanquan
    Jiang Chuner
    Wang Lei
    Yan Fengqin
    Ye Zhimin
    Liu Tongxin
    Xu Min
    Wu Peng
    Jiang Haitao
    Aizawa, Rihito
    Sakamoto, Masoto
    Wang Yuezhen
    Fu Zhenfu
    ONCOTARGET, 2017, 8 (57) : 96798 - 96808
  • [24] Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
    Wang, Yueshu
    Ding, Wei
    Chen, Chuang
    Niu, Zhihao
    Pan, Ming
    Zhang, Hong
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C191 - C195
  • [25] Chemotherapy in locoregionally advanced nasopharyngeal carcinoma-a review
    Krstevska, V.
    Stojkovski, I.
    JOURNAL OF BUON, 2008, 13 (04): : 495 - 503
  • [26] OUTCOME OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA: USING CHEMOTHERAPY AND RADIOTHERAPY
    Khattab, T.
    Baothman, A.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 208 - 208
  • [27] Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma
    Lin, JC
    Chen, KY
    Jan, JS
    Hsu, CY
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (05): : 1127 - 1136
  • [28] The treatment of advanced nasopharyngeal carcinoma with hyperfractionated radiotherapy and chemotherapy
    Fernández, MCF
    López, LD
    Fernández, JLG
    Simón, JL
    Puerto, AG
    Maíllo, M
    Torres, MJJ
    Rey, EA
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 37 - 41
  • [29] Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy
    Wee, Chan Woo
    Keam, Bhumsuk
    Heo, Dae Seog
    Sung, Myung-Whun
    Won, Tae-Bin
    Wu, Hong-Gyun
    RADIATION ONCOLOGY JOURNAL, 2015, 33 (02): : 98 - 108
  • [30] Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
    Hong, RL
    Ting, LL
    Ko, JY
    Hsu, MM
    Sheen, TS
    Lou, PJ
    Wang, CC
    Chung, NN
    Lui, LT
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) : 4305 - 4313